48 cases with bone metastasis from breast cancer were treated by radiation therapy. Result; 1) The effective ratio of radiation therapy on symptomatic relief of pain was 83%. 2) In 90% of effective cases, patients felt pain relief at 20 Gy. 3) For 3 of 7 cases which showed paralysis by vertebral metastasis, radiotherapy was very effective. 4) The patients with only bone metastasis have good prognosis. So, it is important radiotherapy is performed on different outlook.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Combining radiotherapy with targeted therapy benefits patients with advanced epidermal growth factor receptor-mutated non-small cell lung cancer (EGFRm NSCLC). However, the optimal strategy to combine EGFR tyrosine kinase inhibitors (TKIs) with radiotherapy for maximum efficacy and minimal toxicity is still uncertain. Notably, EVs, which serve as communication mediators among tumor cells, play a crucial role in the anti-tumor immune response.
View Article and Find Full Text PDFCharacterization of an Inorganic Powder-Based Scintillation Detector Under a UHDR Electron Beam.
Sensors (Basel)
December 2024
Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
(1) Background: Ultra-high dose rate (UHDR) radiation therapy needs a reliable dosimetry solution and scintillation detectors are promising candidates. In this study, we characterized an inorganic powder-based scintillation detector under a 9 MeV UHDR electron beam. (2) Methods: A mixture of ZnS:Ag powder and optic glue was coupled to an 8 m Eska GH-4001-P polymethyl methacrylate (PMMA) optical fiber.
View Article and Find Full Text PDFInnovative Nanomedicine Delivery: Targeting Tumor Microenvironment to Defeat Drug Resistance.
Pharmaceutics
December 2024
Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China.
Nanodrug delivery systems have revolutionized tumor therapy like never before. By overcoming the complexity of the tumor microenvironment (TME) and bypassing drug resistance mechanisms, nanotechnology has shown great potential to improve drug efficacy and reduce toxic side effects. This review examines the impact of the TME on drug resistance and recent advances in nanomedicine delivery systems to overcome this challenge.
View Article and Find Full Text PDFMesoporous Polydopamine Nano-Bowls Demonstrate a High Entrapment Efficiency and pH-Responsive Release of Paclitaxel for Suppressing A549 Lung Cancer Cell Proliferation In Vitro.
Pharmaceutics
December 2024
Wits Advanced Drug Delivery Platform, Department of Pharmacy and Pharmacology, School of Therapeutic Sciences, Faculty of Health Sciences, University of the Witwatersrand, 7 York Road, Parktown, Johannesburg 2193, South Africa.
The effectiveness of paclitaxel (PTX) in treating non-small-cell lung carcinoma (NSCLC) is restricted by its poor pharmacokinetic profile and side effects. This limitation stems from the lack of a suitable delivery vector to efficiently target cancer cells. Therefore, there is a critical need to develop an efficient carrier for the optimised delivery of PTX in NSCLC therapy.
View Article and Find Full Text PDFNanocarriers for Delivery of Anticancer Drugs: Current Developments, Challenges, and Perspectives.
Pharmaceutics
November 2024
Department of Cell Biology and Molecular Genetics, Sri Devraj Urs Medical College, Sri Devaraj Urs Academy of Higher Education and Research, Kolar 563103, India.
Cancer, the most common condition worldwide, ranks second in terms of the number of human deaths, surpassing cardiovascular diseases. Uncontrolled cell multiplication and resistance to cell death are the traditional features of cancer. The myriad of treatment options include surgery, chemotherapy, radiotherapy, and immunotherapy to treat this disease.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!